Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune System Diseases 1AIDS-Related Complex 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × tetulomab tetraxetan lu-177 × Other hematologic neoplasm × Clear all
NCT02657447 2019-01-10

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Nordic Nanovector

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

AIDS-Related Complex, Immune System Diseases, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡